BERLIN, July 3 (Reuters) – BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper reported on Friday.
The German company had said in May that it would close three sites in Germany – Idar-Oberstein, Marburg and Tuebingen – by the end of 2027, and also end operations in Singapore by the first quarter of next year, affecting up to 1,860 jobs.
According to Handelsblatt, the Berlin-based BioNTech subsidiary JPT Peptides is also being put up for sale.
The maker of peptides used in immunology and drug discovery is no longer profitable, and BioNTech plans to close it by the end of this year, the report said, citing people familiar with the decisions.
BioNTech and JPT Peptides did not immediately respond to emailed requests for comment.
(Writing by Miranda Murray; Editing by Lincoln Feast.)
Comments